Mar 9, 2026
Here at WaveData we keep a close eye on the number of concessions granted to individual products each month and have been doing so since they were launched in November 2010. We have always assumed the Category M is the primary source of concessions and of the linked...
Mar 5, 2026
There has been a lot of discussion about Category H at recent events, online and on socials. Charles Joynson, WaveData MD, poses the question; ‘Will it cut another group of generics to the bone and seriously damage pharmacy and supplier profitability? Or will it...
Feb 13, 2026
Charles Joynson, WaveData MD, was delighted to join Jeremy Durrant, Director of Communications and External Engagement at Medicines UK, in the latest episode of their podcast Medicine Matters. It’s a lively discussion, looking at pricing trends over the last 12...
Sep 16, 2025
Leslie Galloway, EMIG Chairman, shared his analysis of VPAG. Here’s Charles’ key takeaways: · The NHS VPAG rebate is £1bn over 3 years and so is a fixed rebate with risk share. · Global Pharma CEOs have asked for lower rebates and a better deal, that...
Sep 16, 2025
Charles Joynson, WaveData MD, decided to have a look at the differences between the average market price for generics and the English drug tariff. He wanted to know if the gap between the two was being squeezed, resulting in some of the misery pharmacists are going...
Jul 23, 2025
Each month WaveData collects the prices of medicines and devices from pharmacies and dispensing doctors. These come from the price lists and invoices sent to these accounts by their suppliers. So what we’re looking at here is the ‘share of voice’ rather than market...
